Featured Software
The most popular of our software
Some of Our Clients
Latest News
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Vestibulum a lorem velit. Etiam nec nulla a erat hendrerit varius sit amet et enim. Cras id tincidunt erat. Suspendisse facilisis condimentum urna.
Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial under an Innovative Four-company Cooperative Research and Development (CRADA) Contract.
Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone ...
Halberd and Mississippi State University to Commence Stage II Advanced TBI Nasal Spray Testing
Jackson Center, PA February 8, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Traumatic Brain Injury (TBI) mitigating nasal spray ...
Halberd’s Top Executives Join Forces with Athena GTX CEO Mark Darrah Unveiling 2024 Powerful Partnership Outlook on “The Street Reports Podcast”
JACKSON CENTER, PA February 6, 2024 -- Halberd Corporation’s (OTC: HALB) and Athena GTX’s executives interviewed on "The ...